Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AbbVie Knocks Back Ablynx's Vobarilizumab In RA

Executive Summary

A major setback for Ablynx as AbbVie decides not to exercise its opt-in for vobarilizumab in rheumatoid arthritis. Though the competitive landscape of biologics targeting IL-6 casts a shadow over its commercial prospects, Ablynx is determined to continue development.

Advertisement

Related Content

Safety Issues Not Dampening AbbVie Optimism For Humira Successors
Deal Watch: Novartis, Cerulean Team To Develop Nanoparticle-Drug Conjugates
Ablynx Builds Case For AbbVie Option On Humira Successor

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097511

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel